Truist reiterates OmniAb stock Buy rating on biotech recovery By Investing.com

OmniAb reported Q4 FY2025 revenue of $8.4M, down 22.2% year-over-year, with EPS of -$0.11 beating the -$0.13 forecast and a net loss of $14.2M. Truist, Benchmark and Stifel reiterated Buy ratings (Bench PT $4; Stifel PT $9) citing a cash-rich balance sheet (current ratio 4.02), >400-program diversification, 17% growth in active partners and 12% growth in programs, and a 9.7% reduction in operating expenses despite accelerating cash burn. Shares trade at $1.52 (market cap ~$229M) and are down ~36% over the past year; the setup is mixed — analyst optimism and operational improvements countered by falling revenue and continued losses.

Analysis

Platform biotech exposure like OmniAb is functionally a royalty/partner optionality play rather than a classic pipeline binary. That structural tilt means the marginal dollar of improvement in partner R&D spend translates into staged, asymmetric cashflows for the platform — small near-term upside from service milestones and very large but backloaded upside from royalties if one or more partner programs scale. The second-order beneficiaries from an uptick in partner activity are contract development and manufacturing outfits, antibody-engineering tool vendors, and late-stage CROs; conversely, single-asset pre-revenue biotechs remain most exposed to any pullback in partner funding.

Key risks are timing and concentration: upside is lumpy and multi-year, while downside can be front-loaded via equity dilution and accelerating cash burn if milestone receipts lag. Market-moving catalysts are binary partner readouts, large licensing milestone announcements, and any non-dilutive cash inflows (partnerships/royalty monetizations) — expect windows of 1–3 months for PR-driven moves and 12–36 months for royalty realization. Traders should also watch partner cash cycles (big pharm budgeting seasons) as a predictable cadence for deal activity.

The consensus frames this as a defensive way to own biotech optionality, but that understates sequencing risk: analysts often model eventual royalties without fully discounting multi-year realization and milestone waterfall structures. That mismatch creates arbitrageable periods where headline upgrades drive short-term rallies while fundamentals still argue for cautious position sizing and explicit option hedges to control downside over the 12–36 month horizon.

Key Decisions for Investors

• Long OmniAb (OABI) small core position: 1–2% portfolio, buy within next 4–8 weeks on weakness or consolidation. Target 2.5x upside over 12–36 months if 1–2 partner milestones hit; set tactical stop-loss at -40% from entry to limit dilution/timing risk.
• Leverage trade using defined-risk options: purchase OABI Jan 2027 LEAP calls or 18–24 month 150–200% OTM call spreads (if LEAPs unavailable) sized to risk no more than 0.5% of portfolio. Reward scenario is 4x+ if a top-tier partner achieves approval/outsized royalty stream.
• Hedge sector beta: pair long OABI with a short XBI (equal dollar, rebalanced monthly) to isolate platform-specific upside vs broad biotech volatility. This reduces sector-driven drawdowns; expect win if platform milestones outpace general readout cadence within 12 months.
• Event-driven tactical: if a sizable non-dilutive deal, royalty monetization, or multi-program partnership announced, take profits on 30–50% of position; if no material milestones in 12 months and burn remains elevated, exit remaining position.
• Risk-off put protection: buy 6–9 month OABI puts (or put spreads) to cover 50% of position ahead of anticipated partner-readout windows or financing seasons, cost capped at ~1–2% portfolio to limit tail exposure.